Treatment Algorithms in Systemic Lupus Erythematosus

Arthritis Care & Research
Chayawee MuangchanJanet E Pope

Abstract

To establish agreement on systemic lupus erythematosus (SLE) treatment. SLE experts (n = 69) were e-mailed scenarios and indicated preferred treatments. Algorithms were constructed and agreement determined (≥50% respondents indicating ≥70% agreement). Initially, 54% (n = 37) responded suggesting treatment for scenarios; 13 experts rated agreement with scenarios. Fourteen of 16 scenarios had agreement as follows: discoid lupus: first-line therapy was topical agents and hydroxychloroquine and/or glucocorticoids then azathioprine and subsequently mycophenolate (mofetil); uncomplicated cutaneous vasculitis: initial treatment was glucocorticoids ± hydroxychloroquine ± methotrexate, followed by azathioprine or mycophenolate and then cyclophosphamide; arthritis: initial therapy was hydroxychloroquine and/or glucocorticoids, then methotrexate and subsequently rituximab; pericarditis: first-line therapy was nonsteroidal antiinflammatory drugs, then glucocorticoids with/without hydroxychloroquine, then azathioprine, mycophenolate, or methotrexate and finally belimumab or rituximab, and/or a pericardial window; interstitial lung disease/alveolitis: induction was glucocorticoids and mycophenolate or cyclophosphamide, then rituximab or intr...Continue Reading

References

Jan 17, 1991·The New England Journal of Medicine·UNKNOWN Canadian Hydroxychloroquine Study Group
Nov 1, 1988·Journal of the American Academy of Dermatology·R AshinoffA G Franks
Jul 1, 1986·Archives of Dermatology·V Werth, A Franks
Dec 24, 2003·Scandinavian Journal of Rheumatology·Y K ChanH K Ng
Mar 30, 2005·American Journal of Hematology·Peter BraendstrupHans C Hasselbalch
Jun 23, 2006·The New England Journal of Medicine·Donald P TashkinUNKNOWN Scleroderma Lung Study Research Group
Dec 16, 2006·The Journal of Dermatology·Masayoshi SuganoAkimichi Morita
May 17, 2007·Annals of the Rheumatic Diseases·G BertsiasUNKNOWN Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Jul 20, 2007·Rheumatology International·Jae-Wook ChungChang-Hee Suh
Jul 27, 2007·Hematology·L M AledortUNKNOWN International Anti-D Study Group
Dec 24, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Wei ChenXueqing Yu
Apr 12, 2011·Lupus·S AppenzellerA E Clarke
Aug 31, 2011·Seminars in Arthritis and Rheumatism·Javier NarváezJoan Miquel Nolla
Sep 16, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Xiao LiNan Chen
Oct 29, 2011·Autoimmunity Reviews·Cándido Díaz-LagaresUNKNOWN UK-BIOGEAS Registry
Feb 14, 2012·International Journal of Rheumatic Diseases·Md Nazrul IslamJohannes J Rasker
May 5, 2012·Arthritis Care & Research·Bevra H HahnUNKNOWN American College of Rheumatology
Jul 6, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Marc WeidenbuschHans-Joachim Anders
Jul 18, 2012·Nature Reviews. Rheumatology·Daniel J WallaceSwamy R Venuturupalli
Aug 2, 2012·Annals of the Rheumatic Diseases·George K BertsiasUNKNOWN European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association
Nov 28, 2012·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Lorna K HendersonAngela C Webster

❮ Previous
Next ❯

Citations

Nov 13, 2015·Expert Review of Clinical Pharmacology·Shaye KivityYehuda Shoenfeld
Apr 14, 2016·Dermatologic Therapy·Anna Cristina Garza-MayersGideon P Smith
May 18, 2016·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Vladimir Tesar
Nov 12, 2015·Arthritis Care & Research·Martin Michaud, Francis Gaches
Jan 28, 2016·Arthritis Care & Research·Luis A GonzálezGraciela S Alarcón
Nov 3, 2016·Current Opinion in Otolaryngology & Head and Neck Surgery·Janine AmosAdam D Rubin
Feb 17, 2017·Current Opinion in Rheumatology·Maria Dall'Era
Jan 14, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Koji HabeHitoshi Mizutani
Aug 18, 2018·Expert Opinion on Biological Therapy·Oshrat E Tayer-ShifmanZahi Touma
Feb 5, 2019·The Journal of Dermatology·Risa TakamukiManabu Fujimoto
Aug 14, 2019·The British Journal of Dermatology·N Ruth, L Wine Lee
May 14, 2019·Lupus Science & Medicine·Michael D LockshinMary K Crow
Dec 26, 2016·Rheumatology·Bernard Thong, Nancy J Olsen
May 4, 2017·Expert Opinion on Biological Therapy·Vladimir Tesar, Zdenka Hruskova
Mar 13, 2017·Arthritis Research & Therapy·Daniel Toro-DomínguezMarta E Alarcón-Riquelme
Nov 4, 2020·La Revue de médecine interne·M MichelL Terriou
Feb 4, 2021·Modern Rheumatology Case Reports·Kento IchikawaHideaki Nakajima
Feb 20, 2021·Current Problems in Cardiology·David A BulgerRami N Khouzam
Jul 4, 2021·Rheumatic Diseases Clinics of North America·Alberta Y Hoi, Eric F Morand
Aug 27, 2021·Expert Opinion on Drug Safety·Esther F Vicente-RabanedaSantos Castañeda
Dec 6, 2017·Mayo Clinic Proceedings·Christopher L TrautmanFernando F Stancampiano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Autoimmune Disease Therapy

In autoimmune diseases, the immune system responds and attacks self-antigens and damages or impairs the function of the tissues. The treatment for autoimmune diseases often involves immunosuppressive agents, but newer treatments are being investigated. Discover the latest research on autoimmune disease therapy here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.